OT-401
Phase 2
SanofiOT-401 is one of 13 therapeutic programs targeting Sensorineural Hearing Loss. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
17 competitors in Sensorineural Hearing Loss
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsApproved
Aricept
EisaiApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Local Anesthetic
RRennes University Hospital
Phase 3
Platelet Rich Plasma
ZZagazig University
Phase 3
Combination
GSKPhase 1
AM-111
AAuris Medical AG
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for OT-401. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company